Vertex gets label extension for Orkambi in Europe to treat younger patients with most common cystic fibrosis form
Vertex Pharmaceuticals Limitedgot will extend label for its cystic fibrosis children patients treatment Orkambi in Europe, after the Union’s Commissions’ approval.